Ninth Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca’s ENHERTU with the latest based on DESTINY-Breast09 phase 3 trial results Thirteenth Breakthrough Therapy Designation ...

With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Boehringer's Hernexeos is now FDA-approved for patients with HER2-positive NSCLC, bringing it into direct competition with ADC Enhertu.

Boehringer Ingelheim GmbH won approval in the U.S. for its drug to treat a challenging form of lung cancer, offering a growth ...

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, ...

With the FDA approval of its zongertinib in certain non-small cell lung cancer (NSCLC) patients, 175-year-old Boehringer ...

AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

From new payload linkers to artificial intelligence partnerships, advances in ADC pipelines push forward selective cancer therapies that minimize side effects.

Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.